A series of unexplained pneumonia cases were reported in Wuhan, China in December 2019. On 12 January 2020, the World Health Organization (WHO) named the virus as 2019-nCoV, and on 11 February 2020, it was officially named coronavirus disease 2019 (COVID-19). SARS-CoV-2, the virus causing COVID-19, is a beta-coronavirus and is believed to have originated from bats. It is the third known zoonotic coronavirus disease after SARS and MERS. The virus is transmitted primarily through human-to-human contact, with early cases linked to the Huanan seafood market. The case fatality rate varies between studies, ranging from 2.84% to 33%, while the transmission rate is estimated at 2.2 per patient. Symptoms include fever, cough, fatigue, and dyspnea, with severe cases leading to acute respiratory distress syndrome and myocarditis. Diagnosis involves chest CT scans and laboratory tests. There is currently no approved vaccine or specific treatment for SARS-CoV-2, and treatment is primarily symptomatic. Prevention measures include isolation, personal hygiene, and social distancing. The study emphasizes the need for further research on vaccines and effective treatments, as well as the importance of identifying and controlling super-spreaders and asymptomatic cases. The article also highlights the potential for long-term complications, such as pulmonary fibrosis, in recovered patients. The findings provide a reference for future research and public health strategies.A series of unexplained pneumonia cases were reported in Wuhan, China in December 2019. On 12 January 2020, the World Health Organization (WHO) named the virus as 2019-nCoV, and on 11 February 2020, it was officially named coronavirus disease 2019 (COVID-19). SARS-CoV-2, the virus causing COVID-19, is a beta-coronavirus and is believed to have originated from bats. It is the third known zoonotic coronavirus disease after SARS and MERS. The virus is transmitted primarily through human-to-human contact, with early cases linked to the Huanan seafood market. The case fatality rate varies between studies, ranging from 2.84% to 33%, while the transmission rate is estimated at 2.2 per patient. Symptoms include fever, cough, fatigue, and dyspnea, with severe cases leading to acute respiratory distress syndrome and myocarditis. Diagnosis involves chest CT scans and laboratory tests. There is currently no approved vaccine or specific treatment for SARS-CoV-2, and treatment is primarily symptomatic. Prevention measures include isolation, personal hygiene, and social distancing. The study emphasizes the need for further research on vaccines and effective treatments, as well as the importance of identifying and controlling super-spreaders and asymptomatic cases. The article also highlights the potential for long-term complications, such as pulmonary fibrosis, in recovered patients. The findings provide a reference for future research and public health strategies.